Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Novo Nordisk faces a shareholder lawsuit alleging it misled investors about CagriSema's tolerability, per CNBC. The pharmaceutical company's next-generation weight-loss drug disappointed in clinical trials, wiping billions off its market value.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton